Other research analysts have also recently issued research reports about the stock. Baader Bank set a €140.00 ($172.84) target price on shares of Bayer and gave the stock a buy rating in a research report on Thursday, December 14th. Citigroup restated a buy rating on shares of Bayer in a research report on Thursday, December 7th. UBS set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a buy rating in a research report on Thursday, December 7th. DZ Bank restated a buy rating on shares of Bayer in a research report on Monday, December 11th. Finally, JPMorgan Chase & Co. set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a buy rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of €118.23 ($145.96).
Bayer stock opened at €90.35 ($111.54) on Thursday. Bayer has a 1 year low of €91.58 ($113.06) and a 1 year high of €123.82 ($152.86). The company has a market cap of $78,800.00 and a PE ratio of 24.29.
ILLEGAL ACTIVITY WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3298323/goldman-sachs-reiterates-125-00-price-target-for-bayer-bayn.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.